Delivery Order SPE2DP20D0002-SPE2DP26F0983
Award Date 12/1/25
Potential Completion Date 12/9/25
Potential Value $661K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- The Department of Defense's Medical Supply Chain awarded a $165,156.93 delivery order to Teva Pharmaceuticals USA, Inc. on December 1, 2025, for the supply of Adenovirus Type 4 vaccine. This firm-fixed-price delivery order, with an ultimate completion date of December 9, 2025, represents part of Teva's extensive portfolio supporting critical military immunization programs. The contract contains no set-aside designation and will be performed at Teva's manufacturing facility in Parsippany, New...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- The U.S. Department of Defense's Medical Supply Chain awarded Teva Pharmaceuticals USA, Inc. a $165,156.93 firm fixed-price delivery order for Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This delivery order, issued December 1, 2025, represents a continuation of Teva's critical role as a primary supplier under an existing indefinite delivery contract vehicle with the Defense Logistics Agency Troop Support Medical. The award carries no set-aside designation and...
- On December 1, 2025, the Defense Logistics Agency Troop Support Medical awarded a $330,313.86 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. The contract, with an ultimate completion date of December 9, 2025, represents a delivery order issued under an indefinite delivery contract vehicle and will be performed at Teva's facility in Parsippany, New Jersey. This award carries no set-aside designation and is structured as a firm...
- The U.S. Department of Defense, through the Defense Logistics Agency Troop Support Medical, awarded a delivery order valued at $330,313.86 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine. The contract, awarded on July 14, 2025, with a completion date of July 29, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The Department of Defense's Medical Supply Chain issued a delivery order valued at $1.98M to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine, with an ultimate completion date of December 9, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents one of over 150 similar awards to Teva since 2023 under indefinite delivery contract vehicles managed by the Defense Logistics Agency Troop Support Medical. The Adenovirus Type 4 vaccine...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- Teva Pharmaceuticals USA, Inc. has been awarded a $305,393.76 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. Performance will take place in Parsippany, New Jersey through December 2023. This delivery order was issued against an existing contract vehicle and supports the immunization programs of the military. Teva Pharmaceuticals has a history of partnering with subcontractors and receiving contract awards to supply...